antithrombin III deficiency

(redirected from Antithrombin deficiency)

antithrombin III deficiency

Congenital antithrombin III deficiency An AD condition characterized by ↑ risk of DVT and PE. See Antithrombin III.

antithrombin III deficiency

An inherited deficiency of certain protein-splitting enzymes (proteases) which normally participate in the blood clotting cascade sequence. Women with this deficiency are at serious risk of developing THROMBOEMBOLISM in pregnancy and HEPARIN treatment is necessary.
References in periodicals archive ?
3) However, a meta-analysis on thrombophilia in PVT showed a prevalence of antithrombin deficiency (3.
Inherited antithrombin deficiency Type IIb alters what and results in what?
Acutely ill patients may have an antithrombin deficiency, resulting in an inaccurately low aPTT and undue coagulation (Zehnder, Price, & Jin, 2012).
Objectives: To determine the frequency of Protein C Protein S (PC and PS) antithrombin deficiency (AT III) and Factor V Leiden mutation (FVL) as a cause of thrombophilia in the patients with venous thromboembolism (VTE) and cerebrovascular accident (CVA).
Therefore, testing for a congenital antithrombin deficiency would have to be delayed until the patient had discontinued warfarin.
These protein deficiencies/abnormalities are genetic and include entities such as antithrombin deficiency, protein C deficiency, protein S deficiency, Factor V Leiden mutation, prothrombin 20210, and dysfibrinogenemia, among others.
Antithrombin deficiency, the most thrombogenic of all the inherited thrombophilias, also warrants antepartum anticoagulation as well as antithrombin infusions during labor and delivery.
Although there is no direct evidence of HIV infection leading to antithrombin deficiency, it is suspected that antithrombin deficiency is secondary to liver and kidney disorders caused by HIV disease.
Patients with antithrombin deficiency or homozygous FVL need life long anticoagulation after a first VTE event due to high recurrence risk.
for ATryn, an anticoagulant used to prevent blood clots among patients with hereditary antithrombin deficiency, a rare disease.
People with hereditary antithrombin deficiency are at increased risk for venous thromboembolic events, including pulmonary embolism and deep vein thrombosis, which can be life-threatening, particularly in high risk situations.
Atryn aims to prevent excessive blood clots in patients with a disorder known as hereditary antithrombin deficiency.